Voyager shareholders approve doubling authorized shares to 245M

the Certificate of Amendment, which was effective upon filing, with the Secretary of State of the State of Delaware on June 9, 2026

Voyager’s stockholders approved an amendment to the Fifth Amended and Restated Certificate of Incorporation of Voyager Therapeutics, Inc. to increase the number of authorized shares of the Company’s capital stock from 125,000,000 shares to 245,000,000 shares and increase the number of authorized shares of common stock from 120,000,000 shares of common stock to 240,000,000 shares of common stock. The results of the stockholders’ vote with respect to such proposal were as follows: For Against Abstain Broker Non-Votes 43,464,491 2,593,426 108,424 -

Voyager’s stockholders elected James A. Geraghty, Steven Hyman, M.D., and Alfred Sandrock, M.D., Ph.D., each to serve as a Class II director until the 2029 Annual Meeting of Stockholders and until such nominee’s successor has been duly elected and qualified, subject to such nominee’s earlier death, resignation, or removal. The results of the stockholders’ vote with respect to the election of such Class II directors were as follows: Name Votes For Votes Withheld Broker Non-Votes James A. Geraghty 23,336,364 9,772,133 13,057,844 Steven Hyman, M.D. 30,442,488 2,666,009 13,057,844 Alfred Sandrock, M.D., Ph.D. 31,890,428 1,218,069 13,057,844

Voyager’s stockholders approved a non-binding, advisory proposal regarding the compensation of Voyager’s named executive officers. The results of the stockholders’ vote with respect to such proposal were as follows: For Against Abstain Broker Non-Votes 32,041,373 910,087 157,037 13,057,844

Voyager’s stockholders ratified the appointment of Ernst & Young LLP as Voyager’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the stockholders’ vote with respect to such ratification were as follows: For Against Abstain Broker Non-Votes 45,902,883 108,561 154,897 -